محصولات و مطالب رایگان
اندازه گیری شاخص توده بدنی(BMI) ……….. راهنما: زیر 18.5 لاغر …………. طبیعی:25_18.5 ………… اضافه وزن:30_25 …………….. چاقی کلاس یک: 35_30 ……………………..چاقی کلاس دو:40_35………چاقی کلاس سه:40 به بالا ………… Imperial را انتخاب کرده قد و وزن را وارد کنید سپس calculate را بزنید
BMI Calculator
Imperial    Metric
ft in
lbs
Powered by Easy BMI Calculator

تجویز و تعدیل دوز اوسلتامیویر برای پزشکان

اشتراک گذاری
اشتراک گذاری

اوسلتامیویر

لینک دانلود PDF

http://www.drjadid.com/wp-content/uploads/2020/03/تجویز-و-تعدیل-دوز-اوسلتامی-ویر-برای-پزشکان.pdf

Oseltamivir(Tamiflu) Dosing & Uses

ADULTPEDIATRIC

Dosage Forms & Strengths

capsule

  • ۳۰mg
  • ۴۵mg
  • ۷۵mg

powder for oral suspension

  • ۶mg/mL

MORE…

Influenza A and B Prophylaxis

۷۵ mg PO qDay for at least 10 days

Dosing considerations

  • Initiate within 48 hours of exposure
  • For community outbreak, may administer for up to 6 weeks

Influenza A and B Treatment

۷۵ mg PO q12hr for 5 days

Dosing considerations

  • Initiate within 48 hours of influenza symptom onset

H1N1 Influenza A (Swine Flu) Prophylaxis (Off-label)

۷۵ mg PO qDay

Dosing considerations

  • Postexposure prophylaxis: Initiate within 7 days of exposure and continue for at least 10 days
  • Preexposure prophylaxis (community outbreak): Initiate during potential exposure period and continue for 10 days after last known exposure
  • Consider longer duration (>5 days) in severely ill patients who remain severely ill after 5 days of therapy

H1N1 Influenza A (Swine Flu) Treatment (Off-label)

۷۵ mg PO q12hr for 5 days

Dosing considerations

  • Initiate within 48 hours of influenza symptom onset

Dosage Modifications

Renal impairment

  • Treatment
    • CrCl >60 to 90 mL/min: No dosage adjustment necessary
    • CrCl >30 to 60 mL/min: 30 mg PO BID
    • CrCl >10 to 30 mL/min: 30 mg PO qDay
    • End-stage renal disease (ESRD), not undergoing dialysis: Not recommended (not studied)
    • ESRD CrCl ≤۱۰ mL/min; on hemodialysis: 30 mg PO immediately and then 30 mg after every hemodialysis cycle; treatment duration not to exceed 5 days
    • ESRD CrCl ≤۱۰ mL/min; on CAPD: Single dose of 30 mg administered immediately
  • Prophylaxis
    • CrCl >60 mL/min: No dose adjustment necessary
    • CrCl >30 to 60 mL/min: 30 mg PO qDay
    • CrCl >10 to 30 mL/min: 30 mg PO every other day
    • End-stage renal disease (ESRD), not undergoing dialysis: Not recommended (not studied)
    • ESRD CrCl ≤۱۰ mL/min; on hemodialysis: 30 mg PO immediately and then 30 mg after alternate hemodialysis cycle
    • ESRD CrCl ≤۱۰ mL/min; on CAPD: 30 mg immediately and then 30 mg once weekly

Hepatic impairment

  • Mild-to-moderate: No doage adjustment necessary
  • Severe: Not studied

 

Interactions

Enter a drug nameand oseltamivir

All InteractionsSort By:  Severity Name

Contraindicated (0)

Serious – Use Alternative (1)

  • pretomanid

Monitor Closely (8)

  • clopidogrel
  • influenza virus vaccine quadrivalent
  • influenza virus vaccine quadrivalent, intranasal
  • influenza virus vaccine quadrivalent, recombinant
  • influenza virus vaccine trivalent
  • influenza virus vaccine trivalent, adjuvanted
  • influenza virus vaccine trivalent, recombinant
  • probenecid

Minor (0)

Adverse Effects

۱-۱۰%

Abdominal pain

Conjunctivitis

Ear disorder

Epistaxis

Insomnia

Nausea

Vomiting

Vertigo

<1%

Aggravation of diabetes

Anemia

Arrhythmia

Confusion

Delirium

Hemorrhagic colitis

Hepatitis

Humerus fracture

Peritonsillar abscess

Pneumonia

Pseudomembranous colitis

Pyrexia

Rash

Seizure

Transaminases increased

Toxic epidermal necrolysis

Unstable angina

Swelling of face or tongue

Postmarketing Reports

Hypothermia

Diaper rash (2 weeks to <1 year of age)

Dermatitis

Urticaria

Eczema

Stevens-Johnson Syndrome

Erythema multiforme

Gastrointestinal bleeding

Abnormal liver function tests

Next

 

Pregnancy & Lactation

Pregnancy

There are no adequate and well–controlled studies in pregnant women to inform a drug–associated risk of adverse developmental outcomes; available published epidemiological data suggest that the drug, taken in any trimester, is not associated with an increased risk of birth defects; however, these studies individually are limited by small sample sizes, use of different comparison groups, and some lacked information on dose, which preclude a definitive assessment of the risk

Pregnant women are at higher risk of severe complications from influenza, which may lead to adverse pregnancy and/or fetal outcomes including maternal death, still births, birth defects, preterm delivery, low birth weight and small for gestational age

Animal data

  • In animal reproduction studies, no adverse developmental effects were observed at clinically relevant exposures

Lactation

Based on limited published data, have shown the drug to be present in human milk at low levels considered unlikely to lead to toxicity in the breastfed infant; postmarketing experience has not reported any information to suggest serious adverse effects to drug exposure via breast milk in infants; it is not known if drug affects human milk production; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from drug or from underlying maternal condition

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

 

 

نویسنده : دکترجدید
تاریخ انتشار : 09 / 03 / 2020
بازدید :
لینک کوتاه : https://www.drjadid.com/?p=1625